Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | GPR132 | Q9UNW8 | 6/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MC5R | P33032 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.36 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041957 | 0.89 | CTSK (0.42) | CTSKACEMC4RMC5RMC3R | |
| SCHEMBL4044071 | 0.89 | CTSK (0.54) | CTSKACEMC4RMC5RMC3R | |
| SCHEMBL4046951 | 0.88 | CTSK (0.47) | CTSKACEGPR132CMKLR2CMKLR1 | |
| SCHEMBL4042595 | 0.88 | CTSK (0.57) | CTSKACEGPR132CTSLCTSS | |
| SCHEMBL4042871 | 0.88 | CTSK (0.48) | CTSKACEGPR132NPC1TP53 | |
| SCHEMBL4040930 | 0.87 | ACE (0.40) | CTSKACEGPR132MC4RMC5R | |
| SCHEMBL4039009 | 0.85 | CTSK (0.41) | CTSKACEGPR132MC4RMC5R | |
| SCHEMBL4044330 | 0.84 | CTSK (0.41) | CTSKACEGPR132MC4RMC5R | |
| SCHEMBL4042748 | 0.83 | CTSK (0.49) | CTSKACECTSVCTSLCTSS | |
| SCHEMBL4044197 | 0.81 | CTSK (0.63) | CTSKACECTSVCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885ACE 3804/4885GPR132 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.